It’s been estimated that chronic pain affects 7.8 million people in the UK, and it has a significant impact on individuals’ health, quality of life and ability to work. We don’t believe it’s right that chronic pain should prevent people from enjoying the simple things that we take for granted… a visit to the park with your children, an outing to the shops, a good night’s sleep… and that’s why we have been committed to furthering the understanding and treatment of pain for over 30 years.
Unfortunately, one in three of us will develop some form of cancer during our lifetime. Although the treatment of cancer has improved vastly, there is still more that can be done. Napp is passionately committed to the development of innovative cancer treatments and is currently focused on improving the options for those living with blood cancers.
Despite advances in the treatment of asthma since the 1980s, many of the
5.4 million people living in the UK who have asthma still suffer loss of control over their breathing on a daily basis. As well as having a significant impact on their quality of life, this can also become life-threatening. Asthma UK have reported that there were over 79,000 asthma-related admissions to hospital in 2008/9 and that 75% of hospital admissions for asthma are avoidable. This is why we are renewing our commitment to this area.
It has been estimated that rheumatoid arthritis affects three million people across Europe. It mainly affects the joints and tendons in the wrists, hands or feet, but can affect other joints too. The distressing joint stiffness and pain can be much worse in the mornings, making it difficult to complete everyday tasks, such as washing and dressing. This is a new area for us, and we introduced our first product in 2010.